Canada Markets close in 24 mins

Frequency Therapeutics, Inc. (FREQ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.41+0.38 (+7.44%)
As of 03:36PM EST. Market open.

Frequency Therapeutics, Inc.

75 Hayden Avenue
Suite 300
Lexington, MA 02421
United States
781 315 4600
http://www.frequencytx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees83

Key Executives

NameTitlePayExercisedYear Born
Mr. David L. LucchinoCo-Founder, Pres, CEO & Director1.1MN/A1969
Mr. Peter P. PfreundschuhChief Financial Officer535kN/A1969
Ms. Wendy S. ArnoldChief People Officer550.37kN/A1972
Dr. Christopher R. LooseCo­-Founder & Chief Scientific OfficerN/AN/A1981
Mr. William J. McLean Ph.D.Co-founder & Sr. VP of Hearing Biology and Translational ResearchN/AN/AN/A
Mr. Richard J. MitranoVP of Fin. & OperationsN/AN/A1970
Dr. Jeff HrkachSr. VP of Technology Devel.N/AN/A1966
Dr. Dana C. HiltChief Medical OfficerN/AN/A1953
Dr. Carl P. LeBelChief Devel. OfficerN/AN/A1959
Dr. William W. Chin M.D.Sr. VP of Translational MedicineN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Corporate Governance

Frequency Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 10. The pillar scores are Audit: 6; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.